Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward—Results of One Year Extended Study

Dudzicz, Sylwia; Kujawa-Szewieczek, Agata; Kwiecień, Katarzyna; Wiȩcek, Andrzej; Adamczak, Marcin

doi:10.3390/nu10111574

Cited by 35 publications

(33 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have revealed that Lactobacillus has the potential to regulate host immune systems, enhance gut metabolic capacities and maintain balance in the gut microbiota (Hou, Zeng, Yang, Liu, & Qiao, ; Zhang et al, ). Lactobacillus plantarum is considered an excellent probiotic in the gastrointestinal tracts of humans and animals and performs important probiotic actions, such as inhibiting Escherichia coli ‐induced intestinal permeability, reducing the incidence of Clostridium difficile , alleviating oxidative damage to the liver, improving growth performance and increasing intestinal immunity and anti‐inflammatory properties (de Vries, Vaughan, Kleerebezem, & de Vos, ; Dudzicz, Kujawa‐Szewieczek, Kwiecien, Wiecek, & Adamczak, ; Fak, Ahrne, Molin, Jeppsson, & Westrom, ; Herías et al, ; Khanian, Karimi‐Torshizi, & Allameh, ; Malik et al, ; Wullt, Johansson Hagslatt, Odenholt, & Berggren, ). Researches have shown that oral administration of L. plantarum can improve the immune responses and enhance the intestinal barrier function of weaning piglets (Wang, Ji, et al, ; Yang, Jiang, Zheng, Wang, & Yang, ).…”

Section: Introductionmentioning

confidence: 99%

Effects of Lactobacillus plantarum on the intestinal morphology, intestinal barrier function and microbiota composition of suckling piglets

Wang

Sun

et al. 2019

Animal Physiology Nutrition

View full text Add to dashboard Cite

This study investigated the effect of Lactobacillus plantarum strain 299v on gut health in suckling piglets. Sixty newborn piglets were assigned to control and probiotic treatments, with three litters per treatment (ten piglets/litter). From days 1 to 20 of life, piglets were orally administered a placebo of 0.1% peptone or 1.0 × 1010 CFU L. plantarum 299v daily. Six piglets per treatment were sacrificed on day 20, and intestinal tissues (including duodenum, jejunum, ileum and colon) and the intestinal contents from colon segments were collected. The results demonstrated that piglets treated with L. plantarum 299v had a lower diarrhoea incidence than the controls. L. plantarum 299v administration significantly increased the ratio of the villus height to the crypt depth in the jejunum and ileum, as well as the mRNA expression of jejunal occludin and ileal zonula occludens 1 (ZO‐1). The L. plantarum treatment also increased the mRNA abundance of porcine β‐defensin 2 (pBD2) and pBD3 in the jejunum and ileum and of toll‐like receptors (TLRs), such as TLR2, TLR4, TLR6 and TLR9 in the ileum, and significantly upregulated the mRNA abundances of ileal pBD1 and colonic TLR4. Additionally, the L. plantarum 299v treatment significantly changed the structure of the colonic microbiota, as evidenced by the obvious increases in the relative abundances of the phyla Firmicutes and Actinobacteria and of the genus Lactobacillus. Our findings indicate that L. plantarum 299v facilitates the gut health of suckling piglets, probably by improving the intestinal morphology and intestinal barrier function and by modifying the structure of the gut microbiota.

show abstract

Section: Introductionmentioning

confidence: 99%

Effects of Lactobacillus plantarum on the intestinal morphology, intestinal barrier function and microbiota composition of suckling piglets

Wang

Sun

et al. 2019

Animal Physiology Nutrition

View full text Add to dashboard Cite

show abstract

“…Additionally, as it was stated above, L. plantarum 299v is effective in supporting treatment of IBS. Moreover, in Dudzicz et al study, it was confirmed that routine use of L. plantarum 299v may prevent Clostridium difficile infection (CDI) during antibiotic therapy in patients receiving immunosuppressing agents and being hospitalized in nephrology and transplantation ward [17]. Furthermore, the results of Wullt et al study, indicated that L. plantarum 299v reduces the side effects of antibiotics on colonic fermentation in patients suffering from recurrent Clostridium difficileassociated diarrhoea [18].…”

Section: Discussionmentioning

confidence: 90%

The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition – study protocol for a randomized, double-blind, and placebo-controlled trial

Kaźmierczak-Siedlecka

Folwarski

Skonieczna-Żydecka

et al. 2020

Preprint

View full text Add to dashboard Cite

Background Nutritional treatment is one of the most important components of multidisciplinary anti-cancer therapy. Home enteral nutrition is considered as a safe procedure, however, it may be associated with the risk of side effects, such as nausea, vomiting, abdominal pain, and diarrhoea. It is uncertain whether diarrhoea is the result of the enteral formula administration or gut dysbiosis. One of the methods which may be used to alter the composition of gut microbiota is the administration of a probiotic strain. Lactobacillus plantarum 299v ingestion was found to diminish the adverse events of irritable bowel syndrome and Clostridium difficile infection - entities that share the symptoms with enteral nutrition side effects. Therefore, the primary aim of this study is to determine the effect of Lactobacillus plantarum 299v on nutritional status of cancer patients receiving home enteral nutrition. The secondary aims are to evaluate the role of this probiotic strain in the improvement of enteral nutrition tolerance and patients’ quality of life. Methods Forty patients with cancer receiving home enteral nutrition will be enrolled in this clinical trial and randomized to receive one capsule of Lactobacillus plantarum 299v (Sanprobi IBS®) twice a day or placebo for 12 weeks in a double-blind manner. Laboratory tests (the level of albumin, total protein, transferrin, and total lymphocyte count), anthropometric parameters (body mass, the content of fat mass, muscle mass, and total body water), Nutritional Risk Screening (NRS 2002), enteral nutrition tolerance as well as quality of life will be measured. Measurements will be obtained at the baseline and after 4 and 12 weeks of treatment. Discussion The adverse events observed during administration of enteral nutrition have an negative impact on enteral formula tolerance and as a consequence patients’ quality of life. The previous studies have demonstrated that probiotics may reduce the gastrointestinal symptoms related to enteral nutrition. Thus, administration of Lactobacillus plantarum 299v may be effective in improvement of nutritional status, enteral nutrition tolerance, and quality of life of cancer patients receiving home enteral nutrition. Trial registration ClinicalTrials.gov Identifier: NCT03940768

show abstract

“…Additionally, as it was stated above, L. plantarum 299v is effective in supporting treatment of IBS. Moreover, in Dudzicz et al study, it was confirmed that routine use of L. plantarum 299v may prevent Clostridium difficile infection (CDI) during antibiotic therapy in patients receiving immunosuppressing agents and being hospitalized in nephrology and transplantation ward [18]. Furthermore, the results of Wullt et al study, indicated that L. plantarum 299v reduces the side effects of antibiotics on colonic fermentation in patients suffering from recurrent Clostridium difficile-associated diarrhoea [19].…”

Section: Discussionmentioning

confidence: 90%

The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition – study protocol for a randomized, double-blind, and placebo-controlled trial

Kaźmierczak-Siedlecka

Folwarski

Skonieczna-Żydecka

et al. 2020

Nutr J

View full text Add to dashboard Cite

Background Nutritional treatment is one of the most important components of multidisciplinary anti-cancer therapy. Home enteral nutrition is considered as a safe procedure, however, it may be associated with the risk of side effects, such as nausea, vomiting, abdominal pain, and diarrhoea. It is uncertain whether diarrhoea is the result of the enteral formula administration or gut dysbiosis. One of the methods which may be used to alter the composition of gut microbiota is the administration of a probiotic strain. Lactobacillus plantarum 299v ingestion was found to diminish the adverse events of irritable bowel syndrome and Clostridium difficile infection - entities that share the symptoms with enteral nutrition side effects. Therefore, the primary aim of this study is to determine the effect of Lactobacillus plantarum 299v on prevention of weight loss of cancer patients receiving home enteral nutrition. The secondary aims are to evaluate the role of this probiotic strain in the improvement of nutritional status, enteral nutrition tolerance, and patients’ quality of life. Methods Forty patients with cancer receiving home enteral nutrition will be enrolled in this clinical trial and randomized to receive one capsule of Lactobacillus plantarum 299v (Sanprobi IBS®) twice a day or placebo for 12 weeks in a double-blind manner. Laboratory tests (the level of albumin, total protein, transferrin, and total lymphocyte count), anthropometric parameters (body mass, the content of fat mass, muscle mass, and total body water), Nutritional Risk Screening (NRS 2002), enteral nutrition tolerance as well as quality of life will be measured. Measurements will be obtained at the baseline and after 4 and 12 weeks of treatment. Discussion The adverse events observed during administration of enteral nutrition have an negative impact on enteral formula tolerance and as a consequence patients’ quality of life. The previous studies have demonstrated that probiotics may reduce the gastrointestinal symptoms related to enteral nutrition. Thus, administration of Lactobacillus plantarum 299v may be effective in improvement of nutritional status, enteral nutrition tolerance, and quality of life of cancer patients receiving home enteral nutrition. Trial registration ClinicalTrials.gov Identifier: NCT03940768.

show abstract

Lactobacillus plantarum 299v Reduces the Incidence of Clostridium difficile Infection in Nephrology and Transplantation Ward—Results of One Year Extended Study

Cited by 35 publications

References 45 publications

Effects of Lactobacillus plantarum on the intestinal morphology, intestinal barrier function and microbiota composition of suckling piglets

Effects of Lactobacillus plantarum on the intestinal morphology, intestinal barrier function and microbiota composition of suckling piglets

The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition – study protocol for a randomized, double-blind, and placebo-controlled trial

The use of Lactobacillus plantarum 299v (DSM 9843) in cancer patients receiving home enteral nutrition – study protocol for a randomized, double-blind, and placebo-controlled trial

Contact Info

Product

Resources

About